PTI’s management team has many years of drug development experience. Prior to coming together we have successfully put over 25 drugs through the approval process. Our expertise represents a cross-section of drug development disciplines, including preclinical development, clinical development, medical affairs, regulatory, pharmaceutical development and supply chain management.
Chairman of the Board, President & CEO
Remi Barbier has served as PTI's President and Chief Executive Officer since he founded the Company in 1998. Prior to PTI, Mr. Barbier helped in the growth or founding of: Exelixis Inc., a functional genomics company; ArQule, a chemistry company; and EnzyMed (now owned by Albany Molecular Research), a chemistry company. Prior to PTI Mr. Barbier served as Chief Operating Officer of Exelixis. Prior to that, he was Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company. Mr. Barbier received his undergraduate degree from Oberlin College and his graduate degree from the University of Chicago.
Nadav Friedmann PhD, MD
Chief Medical & Operating Officer
Dr. Nadav Friedmann joined PTI as Chief Medical and Operating Officer in October 2001 and has served as a director since September 1998. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various leadership positions, with Johnson & Johnson, a healthcare company, including Vice President and Head of Research of J&J Biotechnology Center. Prior to that, Dr. Friedmann was Medical Director of Abbott Laboratories. Dr. Friedmann is a graduate of Albert Einstein College of Medicine, where he received an MD, and of the University of California, San Diego, where he received a PhD degree in Biochemistry.